Home » Stocks » FLXN

Flexion Therapeutics, Inc. (FLXN)

Stock Price: $11.44 USD -0.03 (-0.26%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 565.14M
Revenue (ttm) 82.90M
Net Income (ttm) -127.58M
Shares Out 49.30M
EPS (ttm) -3.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $11.44
Previous Close $11.47
Change ($) -0.03
Change (%) -0.26%
Day's Open 11.50
Day's Range 10.83 - 11.55
Day's Volume 799,056
52-Week Range 5.01 - 14.39

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 day ago

BURLINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to four new employees consisting of 14,565 restricted st...

Zacks Investment Research - 2 days ago

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 3 days ago

BURLINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2020 financial results after...

Benzinga - 5 days ago

The FDA signed off Flexion Therapeutics Inc's (NASDAQ: FLXN) Phase 1b proof of concept trial evaluating FX301 administered as a popliteal fossa block (a commonly used nerve block in the foot a...

GlobeNewsWire - 6 days ago

BURLINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug ...

GlobeNewsWire - 1 week ago

BURLINGTON, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participat...

Benzinga - 2 weeks ago

Flexion Therapeutics Inc (NASDAQ: FLXN) plans to advance FX201 into the high dose cohort of Phase 1 dose-escalation trial, evaluating the safety and tolerability of FX201 for the treatment of ...

GlobeNewsWire - 1 month ago

- Sheryl Swoopes, WNBA Legend, Basketball Hall of Famer and ZILRETTA Patient, Tips Off Educational Campaign About ZILRETTA and Osteoarthritis Knee Pain - Sheryl Swoopes, WNBA Legend, Basketbal...

Seeking Alpha - 1 month ago

Flexion Therapeutics recently reported their Q4 and full-year 2020 results that revealed record sales for ZILRETTA and encouraging commercial metrics. Despite the COVID-19 headwinds, the compa...

GlobeNewsWire - 1 month ago

BURLINGTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited net sales for the fourth quarter and full year ended Dec...

GlobeNewsWire - 1 month ago

BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participat...

GlobeNewsWire - 2 months ago

BURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participat...

GlobeNewsWire - 3 months ago

BURLINGTON, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to six new employees consisting of 22,798 restricted stoc...

GlobeNewsWire - 4 months ago

BURLINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participat...

Zacks Investment Research - 4 months ago

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for t...

GlobeNewsWire - 4 months ago

BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September 30...

GlobeNewsWire - 4 months ago

BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of th...

Zacks Investment Research - 4 months ago

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

Company to hold conference call today at 8:30 a.m. ET Company to hold conference call today at 8:30 a.m. ET

GlobeNewsWire - 4 months ago

BURLINGTON, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will prese...

GlobeNewsWire - 5 months ago

BURLINGTON, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock...

GlobeNewsWire - 5 months ago

BURLINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will partici...

GlobeNewsWire - 5 months ago

BURLINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in the second cohort of the Phase 1 dose-esc...

GlobeNewsWire - 6 months ago

BURLINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will partici...

GlobeNewsWire - 6 months ago

BURLINGTON, Mass., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President, Clinical Data ...

Zacks Investment Research - 7 months ago

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -8.57% and -0.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the s...

GlobeNewsWire - 7 months ago

BURLINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended June 30, 2...

Investors Business Daily - 7 months ago

A Relative Strength Rating upgrade for Flexion Therapeutics shows improving technical performance. Will it continue?

GlobeNewsWire - 7 months ago

BURLINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2020 financial results and recent busines...

Zacks Investment Research - 7 months ago

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - 7 months ago

FLXN stock has been falling because the company is not in the race for a Covid-19 vaccine. But as that field narrows, FLX is worth a look.

Zacks Investment Research - 7 months ago

Does Flexion Therapeutics (FLXN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 7 months ago

Investors need to pay close attention to Flexion (FLXN) stock based on the movements in the options market lately.

GlobeNewsWire - 7 months ago

BURLINGTON, Mass., July 14, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA net sales of $15.4 million for the quarter ended June 30, 2...

Zacks Investment Research - 7 months ago

Flexion Therapeutics (FLXN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 8 months ago

BURLINGTON, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will particip...

Zacks Investment Research - 9 months ago

Flexion (FLXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Seeking Alpha - 9 months ago

Planning For A Rebound In Flexion Therapeutics

The Motley Fool - 9 months ago

The company priced a share offering, diluting existing shareholders.

GlobeNewsWire - 9 months ago

BURLINGTON, Mass., May 21, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 9,230,770 shares of its common ...

GlobeNewsWire - 9 months ago

BURLINGTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering of $75,000,000 of shares of...

Zacks Investment Research - 9 months ago

Flexion Therapeutics (FLXN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 9 months ago

Flexion Therapeutics' (FLXN) CEO Michael Clayman on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

BURLINGTON, Mass., May 01, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the publication of data from two new analyses of patients treated with ZILRETTA (...

GlobeNewsWire - 10 months ago

BURLINGTON, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced new positive preclinical efficacy and pharmacokinetic (PK) data for FX301, its ...

24/7 Wall Street - 10 months ago

Every time there is major carnage in the stock market, you see top companies trade into the single digits.

Other stocks mentioned: EVRI, HAL, LADR, NOK
GlobeNewsWire - 11 months ago

BURLINGTON, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has entered into an exclusive license agreement with HK Tainuo and Jian...

Seeking Alpha - 11 months ago

Flexion reported positive Q4/2019 earnings in the midst of the Coronavirus Crash. The stock has taken a nosedive to all-time lows and I am looking to take advantage.

Seeking Alpha - 11 months ago

Flexion Therapeutics, Inc. (FLXN) CEO Mike Clayman on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 12.87% and 0.65%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for th...

About FLXN

Flexion Therapeutics, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administere... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Feb 12, 2014
CEO
Michael Clayman
Employees
288
Stock Exchange
NASDAQ
Ticker Symbol
FLXN
Full Company Profile

Financial Performance

In 2019, FLXN's revenue was $72.96 million, an increase of 223.91% compared to the previous year's $22.52 million. Losses were -$149.77 million, -11.72% less than in 2018.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for FLXN stock is "Buy." The 12-month stock price forecast is 20.69, which is an increase of 80.86% from the latest price.

Price Target
$20.69
(80.86% upside)
Analyst Consensus: Buy